ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

$13.61 +0.06 (+0.44%)

(As of 02:15 PM ET)

ARS Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
0

Buy
6

Based on 6 Wall Street analysts who have issued ratings for ARS Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 4 have given a buy rating, and 2 have given a strong buy rating for SPRY.

Consensus Price Target

$24.00
76.34% Upside

According to the 6 analysts' twelve-month price targets for ARS Pharmaceuticals, the average price target is $24.00. The highest price target for SPRY is $30.00, while the lowest price target for SPRY is $19.00. The average price target represents a forecasted upside of 76.34% from the current price of $13.61.

Get the Latest News and Ratings for SPRY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ARS Pharmaceuticals and its competitors.

SPRY Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$24.00	$24.00	$22.75	$14.67
Forecasted Upside	76.34% Upside	42.94% Upside	75.54% Upside	210.08% Upside
Consensus Rating	Buy	Buy	Buy	Hold

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

SPRY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SPRY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ARS Pharmaceuticals Stock vs. The Competition

Type	ARS Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.33	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	77.12% Upside	26,931.60% Upside	9.83% Upside
News Sentiment Rating	Neutral News See Recent SPRY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/8/2024	Cantor Fitzgerald 3 of 5 stars	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00	+117.23%
9/20/2024	Leerink Partners 1 of 5 stars		Boost Target	Outperform ➝ Outperform	$21.00 ➝ $25.00	+69.03%
8/30/2024	William Blair 2 of 5 stars	L. Hanbury-Brown Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/13/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Deschner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$18.00 ➝ $22.00	+102.76%
3/11/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$19.00	+122.48%
3/5/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:31 PM ET.

SPRY Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for ARS Pharmaceuticals is $24.00, with a high forecast of $30.00 and a low forecast of $19.00.
: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last twelve months. There are currently 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRY shares.
: According to analysts, ARS Pharmaceuticals's stock has a predicted upside of 76.34% based on their 12-month stock forecasts.
: Over the previous 90 days, ARS Pharmaceuticals's stock had 1 upgrade by analysts.
: ARS Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, Leerink Partners, and William Blair in the past 90 days.
: Analysts like ARS Pharmaceuticals more than other "medical" companies. The consensus rating for ARS Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SPRY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!

This page (NASDAQ:SPRY) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target